Featured Research

from universities, journals, and other organizations

NIAID Begins Clinical Trial Of West Nile Virus Vaccine

Date:
April 18, 2005
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
A small trial testing the safety of an experimental vaccine targeting West Nile virus (WNV) opened today at the National Institutes of Health's (NIH) Clinical Center in Bethesda, MD. The vaccine, which will be tested first in 15 healthy adult volunteers, was developed for human clinical studies by researchers at the National Institute of Allergy and Infectious Diseases' (NIAID) Vaccine Research Center (VRC), and Vical Inc., San Diego, based on an animal vaccine tested at the CDC. Vical also manufactures the experimental vaccine.

April 18, 2004 -- A small trial testing the safety of an experimental vaccine targeting West Nile virus (WNV) opened today at the National Institutes of Health's (NIH) Clinical Center in Bethesda, MD. The vaccine, which will be tested first in 15 healthy adult volunteers, was developed for human clinical studies by researchers at the National Institute of Allergy and Infectious Diseases' (NIAID) Vaccine Research Center (VRC), and Vical Inc., San Diego, based on an animal vaccine tested at the Centers for Disease Control and Prevention (CDC). Vical also manufactures the experimental vaccine.

Related Articles


"Although the prevalence of West Nile virus disease fluctuates seasonally and regionally, it continues to pose a serious public health threat, especially to older adults and people with weakened immune systems," says Anthony S. Fauci, M.D., director of the NIAID.

WNV, initially isolated in Uganda in 1937, made its first U.S. appearance in New York City in 1999. The virus usually is transmitted to humans through the bite of a mosquito that has been infected after feeding on an infected bird or animal. The virus also can be spread through blood transfusions, organ transplants and breastfeeding, as well as from mother to child during pregnancy. Most people experience no symptoms or only mild symptoms, such as fever, headache and body aches; more serious cases can lead to infections of the brain and nervous system, such as encephalitis or meningitis. In 2004, 2,470 cases of WNV disease were reported in the United States, resulting in 88 deaths. Currently, no WNV vaccine is licensed for use in humans.

The experimental vaccine is composed of a small, circular piece of DNA--called a DNA plasmid--that contains genes that code for two key surface proteins of the West Nile virus. When the vaccine is injected into the muscle, the inner machinery of the muscle cells "reads" the DNA and converts it into two WNV proteins. Recognizing that the proteins are foreign, the muscle cells display them on their surface to alert the body's immune system--both helper T cells, which spur the production of antibodies to block the WNV from gaining entry into cells, and killer T cells, which kill WNV-infected cells outright.

"The DNA vaccine's exploitation of both cellular and antibody immunity offers a potentially potent defense against West Nile virus," says Barney Graham, M.D., Ph.D., chief of the VRC's Clinical Trials Core Laboratory. Adds Dr. Graham, "In our experience in clinical trials, DNA vaccines generally cause few side effects, making them a promising alternative to conventional vaccines."

Although no DNA vaccine has yet been licensed, other DNA vaccines developed by the VRC against HIV/AIDS, Ebola and SARS also are being tested in ongoing trials at NIH.

Fifteen healthy volunteers between the ages of 18 and 50 will receive three injections of the DNA vaccine into the upper arm: one at the start of the trial, a second approximately four weeks later, and a third approximately four weeks after that. To help force the DNA plasmid into muscle cells, the vaccine will be administered by a needle-free injector rather than a conventional needle syringe. Volunteers will be monitored for possible symptoms or side effects as well as the body's ability to generate WNV-specific antibodies and T cells. The vaccine cannot cause West Nile virus infection or disease because it does not contain infectious material from the virus. For more information on the WNV vaccine trial, call the Vaccine Research Center's toll free number 1-866-833-LIFE, or visit the VRC Web site http://www.niaid.nih.gov/vrc/clintrials/clinstudies.htm.

The vaccine in this study builds upon an experimental vaccine developed by CDC researcher Jeff Chang, D.V.M., Ph.D., of Fort Collins, CO, that has been tested successfully in a variety of animals, including mice, horses and American crows.

Two other human WNV vaccines developed with NIAID support are currently in Phase I clinical trials. Called chimeric vaccines, these vaccines combine genes of the West Nile virus with genes of a closely related virus--yellow fever virus in the case of a vaccine developed by Acambis, Cambridge, MA, and dengue virus in the case of a vaccine developed by NIAID intramural researchers.

###

NIAID is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.

News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "NIAID Begins Clinical Trial Of West Nile Virus Vaccine." ScienceDaily. ScienceDaily, 18 April 2005. <www.sciencedaily.com/releases/2005/04/050418202448.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2005, April 18). NIAID Begins Clinical Trial Of West Nile Virus Vaccine. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2005/04/050418202448.htm
NIH/National Institute of Allergy and Infectious Diseases. "NIAID Begins Clinical Trial Of West Nile Virus Vaccine." ScienceDaily. www.sciencedaily.com/releases/2005/04/050418202448.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins